Theseus Pharmaceuticals Inc (DELISTED) (THRX:DL)
4.06
0.00 (0.00%)
USD |
NASDAQ |
Feb 23, 16:00
Price Chart
Key Stats
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. |
| URL | https://www.theseusrx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | |
| Industry | |
| Equity Style | N/A |
| Next Earnings Release | Mar. 08, 2024 (est.) |
| Last Earnings Release | Nov. 17, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. |
| URL | https://www.theseusrx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | |
| Industry | |
| Equity Style | N/A |
| Next Earnings Release | Mar. 08, 2024 (est.) |
| Last Earnings Release | Nov. 17, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |